Eli Lilly commences Covid-19 study with oral JAK1/JAK2 inhibitor baricitinib

This article was originally published here

The phase 3 randomised, double-blind and placebo-controlled study will assess the efficacy and safety of baricitinib, an oral JAK1/JAK2 inhibitor licenced from Incyte, in hospitalised adults with Covid-19.

The post Eli Lilly commences Covid-19 study with oral JAK1/JAK2 inhibitor baricitinib appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply